|
Paul E. Freiman joined NTI as a director and was subsequently appointed President and Chief Executive Officer. He is the former Chairman and Chief Executive Officer of Syntex Corporation, where he had a long and successful career and was instrumental in the sale of Syntex’s lead product, Naprosyn, and was responsible for moving the product to over-the-counter status, marketed by Proctor & Gamble as Aleve. Mr. Freiman currently serves as Chairman of the Board of Penwest Pharmaceuticals Co. He serves on the boards of Calypte Biomedical Corporation, NeoPharm Inc., NovaBay Pharmaceuticals, Otsuka America Pharmaceticals, Inc. and SciGen Ltd. He has also been chairman of the Pharmaceutical Manufacturers Association of Amercia (PhRMA) and has also chaired a number of key PhRMA committees. Mr. Freiman is also an advisor to Burrill & Company, a San Francisco merchant bank. Mr. Freiman holds a B.S. degree from Fordham University and an honorary doctorate from the Arnold & Marie Schwartz College of Pharmacy. | 